We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
- Authors
Eroglu, Zeynep; Krinshpun, Shifra; Kalashnikova, Ekaterina; Sudhaman, Sumedha; Ozturk Topcu, Turkan; Nichols, Matt; Martin, Justin; Bui, Katherine M.; Palsuledesai, Charuta C.; Malhotra, Meenakshi; Olshan, Perry; Markowitz, Joseph; Khushalani, Nikhil I.; Tarhini, Ahmad A.; Messina, Jane L.; Aleshin, Alexey
- Abstract
Background: Immune checkpoint inhibitors (ICIs) have substantially improved overall survival in patients with advanced melanoma; however, the lack of biomarkers to monitor treatment response and relapse remains an important clinical challenge. Thus, a reliable biomarker is needed that can risk‐stratify patients for disease recurrence and predict response to treatment. Methods: A retrospective analysis using a personalized, tumor‐informed circulating tumor DNA (ctDNA) assay on prospectively collected plasma samples (n = 555) from 69 patients with advanced melanoma was performed. Patients were divided into three cohorts: cohort A (N = 30), stage III patients receiving adjuvant ICI/observation; cohort B (N = 29), unresectable stage III/IV patients receiving ICI therapy; and cohort C (N = 10), stage III/IV patients on surveillance after planned completion of ICI therapy for metastatic disease. Results: In cohort A, compared to molecular residual disease (MRD)‐negative patients, MRD‐positivity was associated with significantly shorter distant metastasis‐free survival (DMFS; hazard ratio [HR], 10.77; p =.01). Increasing ctDNA levels from the post‐surgical or pre‐treatment time point to after 6 weeks of ICI were predictive of shorter DMFS in cohort A (HR, 34.54; p <.0001) and shorter progression‐free survival (PFS) in cohort B (HR, 22; p =.006). In cohort C, all ctDNA‐negative patients remained progression‐free for a median follow‐up of 14.67 months, whereas ctDNA‐positive patients experienced disease progression. Conclusion: Personalized and tumor‐informed longitudinal ctDNA monitoring is a valuable prognostic and predictive tool that may be used throughout the clinical course of patients with advanced melanoma. Personalized and tumor‐informed longitudinal circulating tumor DNA monitoring is a valuable prognostic and predictive tool that can be used throughout the clinical course of patients with advanced melanoma, including post surgery adjuvant therapy, during therapy for metastatic disease, and post therapy surveillance.
- Subjects
CIRCULATING tumor DNA; THERAPEUTICS; IMMUNE checkpoint inhibitors; MELANOMA; OVERALL survival; PROGRESSION-free survival
- Publication
Cancer (0008543X), 2023, Vol 129, Issue 11, p1723
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.34716